Time to relapse in patients with moderate to severe psoriasis who were tildrakizumab responders at week 28: Post hoc analysis through 64 weeks from the reSURFACE 1 trial
Por:
Reich, K, Carrascosa, JM, Fumero, E, Lopez, AS and Lebwohl, M
Publicada:
1 dic 2020
Resumen:
Filiaciones:
Reich, K:
Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
:
Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Barcelona, Spain
Fumero, E:
Almirall, Barcelona, Spain
Lopez, AS:
Almirall, Barcelona, Spain
Lebwohl, M:
Icahn Sch Med Mt Sinai, New York, NY 10029 USA
|